NCT00643396|CompletedPhase 2
Loading search results
Sponsor study identifier
interventional
30
1 country
1
Study Start
February 2008
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2012
Actual (reported)Study Completion
January 2012
Actual (reported)The majority of patients with small cell lung cancer have incurable extensive stage disease. The usual initial treatment for this condition is chemotherapy which produces responses in about 50-80% of patients. Despite this, the cancer usually returns. Once common body region where it re-grows is in the chest, which can cause symptoms such as shortness of breath, cough, difficulty swallowing, pain and bleeding. These symptoms can worsen a patient's quality of life and in some situation be life-threatening. In this study , we propose to give patients who have extensive stage small cell lung cancer which responds to chemotherapy radiotherapy treatments to the chest. By giving this type of radiation before the cancer has a chance to re-grow, we hope to control the disease within the chest and prevent future symptoms that it may cause if the cancer were to re-grow in the chest. Patients treated on the protocol will be checked regularly for disease control, quality of life and radiation side effects, if any.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2012
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2008
Date type not reportedThis date has not been verified as actual or estimated.
March 24, 2008
Actual (reported)March 26, 2008
Actual (reported)January 2012
Actual (reported)January 2012
Actual (reported)local control
we anticipate completing accrual to the study in 12 months with most local failure events occuring within 2 years of treatment
radiotherapy toxicities
1-2 years after study treatment
patient quality of life
1-2 years after study treatment
overall survival
1-2 years after study treatment
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
Don Yee, MD, FRCPC
AHS Cancer Control Alberta
30 participants (actual enrollment reported by the registry).
First Submitted
March 24, 2008
First Posted
March 26, 2008
Study Start
February 2008
Date type not reportedThis date has not been verified as actual or estimated.
Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer
Contact the study team to confirm eligibility.
Primary Completion
January 2012
Actual (reported)Study Completion
January 2012
Actual (reported)Last Updated
February 26, 2016
Record last verified: 2012-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: